参考文献
[1]GAO W, WANG K, MA N, et al. Living donor liver transplantations for pediatric patients withbiliary atresia in a single center: 306[J]. Chin J Organ Transplant, 2019, 41(1): 13-17.(in Chinese)
高伟, 王凯, 马楠, 等. 亲属活体肝移植治疗儿童胆道闭锁306例临床分析[J]. 中华器官移植杂志, 2019, 41(1): 13-17.
[2]NEPOM GT, ST CLAIR EW, TURKA LA. Challenges in the pursuit of immune tolerance[J]. Immunol Rev, 2011, 241(1): 49-62.
[3]WALDMANN H. Tolerance: An overview and perspectives[J]. Nat Rev Nephrol, 2010, 6(10): 569-576.
[4]de la GARZA RG, SAROBE P, MERINO J, et al. Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance[J]. Liver Transpl, 2013, 19(9): 937-944.
[5]STARZL TE, DEMETRIS AJ, TRUCCO M, et al. Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance[J]. Hepatology, 1993, 17(6): 1127-1152.
[6]MAZARIEGOS GV, REYES J, MARINO IR, et al. Weaning of immunosuppression in liver transplant recipients[J]. Transplantation, 1997, 63(2): 243-249.
[7]ORLANDO G, MANZIA T, BAIOCCHI L, et al. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: The updated follow up at 78 months[J]. Transpl Immunol, 2008, 20(1-2): 43-47.
[8]BENSELER V, TAY SS, BOWEN DG, et al. Role of the hepatic parenchyma in liver transplant tolerance: A paradigm revisited[J]. Dig Dis, 2011, 29(4): 391-401.
[9]CRISPE IN. Immune tolerance in liver disease[J]. Hepatology, 2014, 60(6): 2109-2117.
[10]SCHILDBERG FA, SHARPE AH, TURLEY SJ. Hepatic immune regulation by stromal cells[J]. Curr Opin Immunol, 2015, 32: 1-6.
[11]DEMETRIS AJ, BELLAMY CO, GANDHI CR, et al. Functional immune anatomy of the liver-as an allograft[J]. Am J Transplant, 2016, 16(6): 1653-1680.
[12]DEMETRIS AJ, MURASE N, NAKAMURA K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection[J]. Semin Liver Dis, 1992, 12(1): 51-59.
[13]FENG S, EKONG UD, LOBRITTO SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants[J]. JAMA, 2012, 307(3): 283-293.
[14]TAKATSUKI M, UEMOTO S, INOMATA Y, et al. Weaning of immunosuppression in living donor liver transplant recipients[J]. Transplantation, 2001, 72(3): 449-454.
[15]DIJKE IE, HOEPPLI RE, ELLIS T, et al. Discarded human thymus is a novel source of stable and long-lived therapeutic regulatory T cells[J] . Am J Transplant, 2016, 16(1): 58-71.
[16]FOOTE JB, KOK M, LEATHERMAN JM, et al. A sting agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice[J]. Cancer Immunol Res, 2017, 5(6): 468-479.
[17]KUMAR P, ALHARSHAWI K, BHATTACHARYA P, et al. Soluble OX40L and JAG1 induce selective proliferation of functional regulatory Tcells independent of canonical TCR signaling[J]. Sci Rep, 2017, 7: 39751.
[18]BAEYENS A, SAADOUN D, BILLIARD F, et al. Effector T cells boost regulatory T cell expansion by IL-2, TNF, OX40, and plasmacytoid dendritic cells depending on the immune context[J]. J Immunol, 2015, 194(3): 999-1010.
[19]FEHR T, SYKES M. Clinical experience with mixed chimerism to induce transplantation tolerance[J]. Transpl Int, 2008, 21(12): 1118-1135.
[20]MATHEW JM, LEVENTHAL JR, MILLER J. Microchimerism in promoting graft acceptance in clinical transplantation[J]. Curr Opin Organ Transplant, 2011, 16(4): 345-352.
[21]SCANDLING JD, BUSQUE S, SHIZURU JA, et al. Induced immune tolerance for kidney transplantation[J]. N Engl J Med, 2011, 365(14): 1359-1360.
[22]MORRIS H, DEWOLF S, ROBINS H, et al. Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplantpatients[J]. Sci Transl Med, 2015, 7(272): 272ra10.
[23]HUTCHINSON JA, RIQUELME P, SAWITZKI B, et al. Cutting edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients[J]. J Immunol, 2011, 187(5): 2072-2078.
[24]BZIE S, PICARDA E, OSSART J, et al. Compensatory regulatory networks between CD8 T, B, and myeloid cells in organ transplantation tolerance[J]. J Immunol, 2015, 195(12): 5805-5815.
[25]WANG K, LIU K, ZHOU CL, et al. Expressions of Treg/Th17 cells in post liver transplantation acute rejection in pediatric recipients diagnosed with biliary atresia[J]. Chin J Hepatobiliary Surg, 2019, 25(1): 5-9.(in Chinese)
王凯, 刘凯, 周春雷, 等. Treg/Th17细胞在胆道闭锁儿童肝移植术后急性排斥反应中的变化[J]. 中华肝胆外科杂志, 2019, 25(1): 5-9.
[26]TAUBERT R, DANGER R, LONDOO MC, et al. Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are downregulated[J]. Am J Transplant, 2016, 16(4): 1285-1293.
[27]HAJKOVA M, HERMANKOVA B, JAVORKOVA E, et al. Mesenchymal stem cells attenuate the adverse effects of immunosuppressive drugs on distinct T cell subopulations[J]. Stem Cell Rev, 2017, 13(1): 104-115.
[28]WHITEHOUSE G, GRAY E, MASTORIDIS S, et al. IL-2 therapy restores the impaired function of regulatory T cells induced by calcineurin inhibitors[J]. Proc Natl Acad Sci U S A, 2017, 114(27): 7083-7088.
[29]KIM N, CHO SG. Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applicationsTracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplantpatients[J]. Int J Hematol, 2016, 103(2): 129-137.
[30]YOUNG JS, YIN D, VANNIER AGL, et al. Equal expansion of endogenous transplant-specific regulatory T cell and recruitment into the allograft during rejection and tolerance[J]. Front Immunol, 2018, 9: 1385.
[31]TODO S, YAMASHITA K, GOTO R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation[J]. Hepatology, 2016, 64(2): 632-643.
[32]BRUNSTEIN CG, MILLER JS, MCKENNA DH, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: Kinetics, toxicity profile, and clinical effect[J]. Blood, 2016, 127(8): 1044-1051.
[33]WANG K, JIAGN WT, GAO W, et al. Effects of different immunosuppressants on peripheral CD4+ CD25+ FoxP3+ regulatory T cells in post liver transplant patients[J]. Chin J Gen Surg, 2015, 30(2): 135-139.(in Chinese)
王凯, 蒋文涛, 高伟, 等. 不同免疫抑制剂对肝移植术后CD4+CD25+FoxP3+调节性T细胞的影响[J]. 中华普通外科杂志, 2015, 30(2): 135-139.
[34]HULL CM, NICKOLAY LE, ESTORNINHO M, et al. Generation of human islet-specific regulatory T cells by TCR gene transfer[J] . J Autoimmun, 2017, 79: 63-73.
[35]BOARDMAN D, MAHER J, LECHLER R, et al. Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?[J]. Biochem Soc Trans, 2016, 42(2): 342-348.
[36]ZHANG Q, LU W, LIANG CL, et al. Chimeric Antigen Receptor (CAR) Treg: A promising approach to inducing immunological tolerance[J]. Front Immunol, 2018, 9: 2359.
[37]BOURDEAUX C, PIRE A, JANSSEN M, et al. Prope tolerance after pediatric liver transplantation[J]. Pediatr Transplant, 2013, 17(1): 59-64.
[38]Banff Working Group on Liver Allograft Pathology. Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance[J]. Liver Transpl, 2012, 18(10): 1154-1170.
[39]BENTEZ C, LONDOO MC, MIQUEL R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients[J]. Hepatology, 2013, 58(5): 1824-1835
[40]DEMETRIS AJ, ISSE K. Tissue biopsy monitoring of operational Tolerance in liver allograft recipients[J]. Curr Opin Organ Transplant, 2013,18(3): 345-353.
[41]FENG S, DEMETRIS AJ, SPAIN KM, et al. Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R[J]. Hepatology, 2017, 65(2): 647-660.
[42]WAKI K, SUGAWARA Y, MIZUTA K, et al. Predicting operational tolerance in pediatric living-donor liver transplantation by absence of HLA antibodies[J]. Transplantation, 2013, 95(1): 177-183.
[43]OHE H, WAKI K, YOSHITOMI M, et al. Factors affecting operational tolerance after pediatric living-donor liver transplantation: Impact of early post-transplant events and HLA match[J]. Transpl Int, 2012, 25(1): 97-106.
[44]YOSHITOMI M, KOSHIBA T, HAGA H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation[J]. Transplantation, 2009, 87(4): 606-614.
[45]LEE JH, LEE SK, LEE HJ, et al. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea[J]. Yonsei Med J, 2009, 50(6):784-788.
[46]LIN NC, WANG HK, YEH YC, et al. Minimization or withdrawal of immunosuppressants in pediatric liver transplant recipients[J]. J Pediatr Surg, 2015, 50(12): 2128-2133.
[47]KIM JJ, MARKS SD. Long-term outcomes of children after solid organ transplantation[J]. Clinics (Sao Paulo), 2014, 69(Suppl 1): 28-38.
[48]JHUN J, LEE SH, LEE SK, et al. Serial monitoring of immune markers being represented regulatory T Cell/T helper 17 cell ratio: Indicating tolerance for tapering immunosuppression after liver transplantation[J]. Front Immunol, 2018, 9: 352.
[49]LAU AH, VITALONE MJ, HAAS K, et al. Mass cytometry reveals a distinct immunoprofile of operational tolerance in pediatric liver transplantation[J]. Pediatr Transplant, 2016, 20(8): 1072-1080.
[50]KONG X, SUN R, CHEN Y, et al. γδT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance[J]. J Immunol, 2014, 193(4): 1645-1653.
[51]ZHAO X, LI Y, OHE H, et al. Intragraft Vδ1 γδ T cells with a unique T-cell receptor are closely associated with pediatricsemiallogeneic liver transplant tolerance[J]. Transplantation, 2013, 95(1): 192-202.
[52]PUIG-PEY I, BOHNE F, BENTEZ C, et al. Characterization of γδ T cell subsets in organ transplantation[J]. Transpl Int, 2010, 23(10): 1045-1055.
[53]GOLDSCHMIDT I, KARCH A, MIKOLAJCZYK R, et al. Immune monitoring after pediatric liver transplantation- the prospective ChilSFree cohort study[J]. BMC Gastroenterol, 2018, 18(1): 63.
[54]LI L, WOZNIAK LJ, RODDER S, et al. A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation[J]. Am J Transplant, 2012, 12(5): 1218-1228.
[55]ZHONG KB, ZHANG P, HE XS, et al. Immune parameters to serve as biomarkers and clinical significance in tolerant patients after liver transplantations[J]. Chin J Hepatobiliary Surg, 2016, 22 (2):78-81. (in Chinese)
钟克波, 张鹏, 何晓顺, 等. 肝移植术后免疫耐受患者相关指标的变化及其临床意义[J]. 中华肝胆外科杂志, 2016, 22 (2):78-81.
[56]KOSHIBA T, LI Y, TAKEMURA M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation[J]. Transpl Immunol, 2007, 17(2): 94-97.
[57]LIU XQ, HU ZQ, PEI YF, et al. Clinical operational tolerance in liver transplantation: state-of-the-art perspective and future prospects[J]. Hepatobiliary Pancreat Dis Int, 2013, 12(1): 12-33.
[58]DEMETRIS AJ, LUNZ JG, RANDHAWA P, et al. Monitoring of human liver and kidney allograft tolerance: A tissue/histopathology perspective[J]. Transpl Int, 2009, 22(1): 120-141.
[59]MIYAGAWA-HAYASHINO A, YOSHIZAWA A, UCHIDA Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts[J]. Liver Transpl, 2012, 18(11): 1333-1342.
[60]SANADA Y, MATSUMOTO K, URAHASHI T, et al. Protocol liver biopsy is the only examination that can detect mid-term graft fibrosis after pediatric liver transplantation[J]. World J Gastroenterol, 2014, 20(21): 6638-6650.
[61]VENTURI C, SEMPOUX C, QUINONES JA, et al. Dynamics of allograft fibrosis in pediatric liver transplantation[J]. Am J Transplant, 2014, 14(7): 1648-1656.
[62]PONS JA, RAMREZ P, REVILLA-NUIN B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients[J]. Clin Transplant, 2009, 23(3): 329-336.
[63]PERITO ER, MOHAMMAD S, ROSENTHAL P, et al. Posttransplant metabolic syndrome in the withdrawal of immunosuppression in Pediatric Liver Transplant Recipients(WISP-R) pilot trial[J]. Am J Transplant, 2015, 15(3): 779-785.
[64]ZHENG HB, WATKINS B, TKACHEV V, et al. The knife’s edge of tolerance: Inducing stable multilineage mixed chimerism but with a significant risk of CMV reactivation and disease in rhesus macaques[J]. Am J Transplant, 2017, 17(3): 657-670.
[65]FENG S, BUCUVALAS J. Tolerance after liver transplantation: Where are we?[J]. Liver Transpl, 2017, 23(12): 1601-1614.